Abstract
Background Tapentadol is an opioid approved for the treatment of moderate-to-severe pain in the United States (US). Tapentadol is unique as it is the only Schedule II prescription drug that has dual modes of action as it combines agonist activity at the µ opioid receptor with norepinephrine reuptake inhibition. This descriptive study characterized tapentadol use in the US.
Methods Drug distribution data from 2010 to 2020 were extracted for each state from the Drug Enforcement Administration. Use per state, corrected for population, was analyzed. The percentage of distribution channels (pharmacies, hospitals, and providers), the distributed amount of tapentadol, and the final adjusted quota of tapentadol were obtained. Data on tapentadol use as reported by the Medicare and Medicaid programs for 2010 to 2020 were also analyzed.
Results The distributed amount of tapentadol was 3.5 tons in 2020 and on average, the final adjusted production quota was 207.2% greater than the distributed amount between 2010 and 2020. Distributed tapentadol was 1.3% of all Schedule II opioids distributed in 2020. Tapentadol use decreased by −53.8% between 2012 and 2020 in the US whereas New Hampshire was the only state that had a positive change (+13.1%). There were minor changes in the amounts of tapentadol distributed via various distribution channels (Pharmacies = 98.0%, hospitals = 1.9% in 2020). Tapentadol prescribed by Nurse Practitioners experienced the largest increase of +8.7% among all specialties to 18.0%, the highest percentage of Medicare claims of tapentadol in 2019. Diabetes prevalence was significantly correlated with tapentadol distribution in 2012 (r(50) = .44, p < .01) and 2020 (r(50) = .28, p < .05).
Discussion There has been a substantial decline over the past decade in tapentadol distribution and prescribing to Medicaid patients. The unusual tapentadol prescribing pattern in New Hampshire may warrant investigation regarding differing prescribers’ attitudes towards tapentadol or the employment of tapentadol as part of a step-down therapy for opioid addiction.
Competing Interest Statement
BJP was part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Funding Statement
This study did not receive any external funding. BJP was supported by the Health Resources Services Administration (D34HP31025). The software used for this report was provided by NIEHS (T32-ES007060-31A1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* bpiper{at}som.geisinger.edu; psy391{at}gmail.com
Disclosures: BJP was part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html
